Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.
BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.
How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?
Препарат Lemtrada, выпускаемый фармацевтической компанией Sanofi Genzyme, был включен в государственную корзину медицинских услуг еще пару лет назад, но в 2017 году критерии его назначения стали более широкими.
Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.
Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.
Фармкомпании могут получать деньги только за эффективные препараты. Об этом сообщает РБК со ссылкой на копию распоряжения вице-премьера Игоря Шувалова. Шувалов...
Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.
Alnylam Pharmaceuticals, Inc. (ALNY) announced that Genzyme, the specialty care global business unit of Sanofi (SNY), has elected to opt in to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe.
Alnylam (ALNY) reported a loss of $1.21 per share in the third quarter of 2016 on revenues of $13.7 million.